Connection

SAMEER JHAVAR to Middle Aged

This is a "connection" page, showing publications SAMEER JHAVAR has written about Middle Aged.
Connection Strength

0.210
  1. Risk factors for locoregional relapse after radical nephrectomy. Asia Pac J Clin Oncol. 2018 Jun; 14(3):192-197.
    View in: PubMed
    Score: 0.033
  2. Intensity modulated radiation therapy after extra-pleural pneumonectomy for malignant pleural mesothelioma is feasible without fatal pulmonary toxicity and provides good survival. Asia Pac J Clin Oncol. 2018 Apr; 14(2):e88-e94.
    View in: PubMed
    Score: 0.033
  3. Durability of Artificial Urinary Sphincter With Prior Radiation Therapy. Clin Genitourin Cancer. 2017 04; 15(2):e175-e180.
    View in: PubMed
    Score: 0.031
  4. Biopsy tissue microarray study of Ki-67 expression in untreated, localized prostate cancer managed by active surveillance. Prostate Cancer Prostatic Dis. 2009; 12(2):143-7.
    View in: PubMed
    Score: 0.018
  5. Glutathione S-transferase M1 or T1 null genotype as a risk factor for developing multiple primary neoplasms in the upper aero-digestive tract, in Indian males using tobacco. Oral Oncol. 2004 Jan; 40(1):84-91.
    View in: PubMed
    Score: 0.013
  6. Holmium Laser Enucleation of Prostate in Patients with Pre-Existing Localized Prostate Cancer, Dual Center Study. J Endourol. 2023 03; 37(3):330-334.
    View in: PubMed
    Score: 0.012
  7. Ad Astra - telomeres in space! Int J Radiat Biol. 2022; 98(3):395-403.
    View in: PubMed
    Score: 0.011
  8. Primary extranodal mucosa associated lymphoid tissue (MALT) lymphoma of the prostate. Leuk Lymphoma. 2001 Apr; 41(3-4):445-9.
    View in: PubMed
    Score: 0.011
  9. Multicentric breast cancer: clonality and prognostic studies. Breast Cancer Res Treat. 2011 Oct; 129(3):703-16.
    View in: PubMed
    Score: 0.005
  10. Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. Br J Cancer. 2010 Sep 07; 103(6):918-24.
    View in: PubMed
    Score: 0.005
  11. The carrier clinic: an evaluation of a novel clinic dedicated to the follow-up of BRCA1 and BRCA2 carriers--implications for oncogenetics practice. J Med Genet. 2010 Jul; 47(7):486-91.
    View in: PubMed
    Score: 0.005
  12. Dynamic contrast-enhanced MRI for prostate cancer localization. Br J Radiol. 2009 Feb; 82(974):148-56.
    View in: PubMed
    Score: 0.005
  13. TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer. Br J Cancer. 2008 Dec 02; 99(11):1849-58.
    View in: PubMed
    Score: 0.005
  14. Correlation of diffusion-weighted MRI with whole mount radical prostatectomy specimens. Br J Radiol. 2008 Jun; 81(966):456-62.
    View in: PubMed
    Score: 0.004
  15. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol. 2008 Apr; 9(4):342-51.
    View in: PubMed
    Score: 0.004
  16. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet. 2008 Mar; 40(3):316-21.
    View in: PubMed
    Score: 0.004
  17. Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene. 2008 Mar 27; 27(14):1993-2003.
    View in: PubMed
    Score: 0.004
  18. Macrophage scavenger receptor 1 999C>T (R293X) mutation and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2005 Feb; 14(2):397-402.
    View in: PubMed
    Score: 0.004
  19. Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome. Oncogene. 2004 Aug 05; 23(35):5871-9.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.